Members of our OC’s Wealthiest list—the centerpiece of a Special Report that starts on page 15— enjoyed a good turn in terms of their finances over the past 12 months, even with the sharp dip for the Dow Jones late last week.
The quick takeaway from last week’s Allergan action: Round 1 goes to David Pyott on points—and an acquisition would knock Valeant out cold
The Insider isn’t ready to make a flat-out prediction but will say this much on the latest turn in the Allergan-Valeant saga: It looks as though David Pyott can play for a tie while his opponents have to win—and do it in regulation time.
Sheril Liu of ReMax Premier Realty in Irvine put a clear focus on one of the ways the city—with a population a bit under 250,000—punches above its weight.
There’s been much consternation about the relatively slow pace of employment growth nationally, even with last week’s report of a big gain on jobs in June.
Here’s one way to look at things as the dust settles on last week’s action in the hostile bid for Allergan by Valeant Pharmaceuticals and Pershing Square’s Bill Ackman: Allergan boss David Pyott’s less-is-more approach on PR tops the raiders’ tendency to work the press at each turn of the drama.
How did the multibillionaire Koch brothers raise $60 million over lunch last week at the Ritz-Carlton in Dana Point?
President Barack Obama was getting close to OC as the Insider went to press, carrying the promise of plenty of memories for UCI grads set to hear his commencement address at Angel Stadium.
Look who’s feeling fresh in brand-new digs—Bill Gross, who joined the rest of the Pimco crew for hot dogs and burgers on the porch of their recently completed HQ in Newport Center last week.
This week’s Special Issue features the OC 50, our annual inventory of influence, which has included David Pyott ever since 1998, shortly after he signed on as CEO of Allergan Inc.
California Chrome was the chalk horse heading into the Kentucky Derby on May 3, continuing a streak of OC ties that started in 2012, when CashCall Inc.’s Paul Reddam saw his I’ll Have Another win at 15-1.
Has anyone looked more the part of the 1980s corporate raider than Bill Ackman as he circles Allergan as a main character in Valeant Pharmaceuticals’ $47 billion hostile bid for the Irvine-based drug maker?
Put local lawyer John Hueston of Irell & Manella somewhere around the front of the line on Texas-based Anadarko Petroleum Corp.’s recent agreement to pay $5.15 billion to settle claims of 85 years’ worth of environmental damage caused across the U.S. by its Kerr-McGee subsidiary.
The so-called smart money says Jerry Brown is unbeatable
No cynics allowed here, but give a bit of room for some healthy skepticism on Facebook’s $2 billion deal for Irvine-based startup Oculus VR.